Regentis Biomaterials raises $15m

Ehud Geller

Chinese pharmaceutical group Haisco led the investment in the Israeli cartilage treatment startup.

Israeli startup Regentis Biomaterials has closed a $15 million Series D financing round led by Chinese pharmaceutical group Haisco with participation from existing investors Medica Venture Partners, SCP Vitalife Partners, Italian asset manager Generali Investment, and the technology transfer company of the Technion, T3.

The company, which is developing products to treat damaged cartilage, has raised $35 million to date including the latest financing round.

Based in Or Akiva between Tel Aviv and Haifa, Regentis Biomaterials was founded in 2004 and is managed by by CEO and President Dr. Alastair Clemow. He said, "We are excited to begin working with Haisco to expand the technological potential of our product for the Chinese market in the coming few years."

Regentis Biomaterials develops hydrogels for tissue regeneration originally developed at the Technion University by Dr. Dror Seliktar. The company’s flagship product, GelrinC, combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance. Currently the treatment is under clinical trials for the treatment of articular cartilage lesions.

The company's products already has approval for sale in Europe and clinical trials will soon begin for US Food and Drug Administration (FDA) approval.

Medica Venture Partners managing partner Dr. Ehud Geller said, "This latest financing round comes after major progress and success in developing the company's leading product and its clinical trials."

Published by Globes [online], Israel business news - www.globes-online.com - on February 7, 2016

© Copyright of Globes Publisher Itonut (1983) Ltd. 2016

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017